Navigation Links
Galenea Announces Publication Describing High Throughput Screening System for Modulators of Synaptic Function
Date:10/6/2011

CAMBRIDGE, Mass., Oct. 6, 2011 /PRNewswire/ -- Galenea Corp., a leader in the rapidly emerging field of synaptic transmission, today announced the publication of a paper in PLoS ONE demonstrating the development and validation of the MANTRA (Multiwell, Automated NeuroTRansmission Assay) system, Galenea's proprietary technology that enables high throughput screening of synaptic function directly on cultured primary neurons.  Changes in synaptic function are now believed to play a central role in many psychiatric, neurological and neurodegenerative diseases.  The MANTRA system can identify both novel drug targets and compounds that modulate disease-related synaptic dysfunction and is expected to yield new mechanism-based therapeutics for schizophrenia, Alzheimer's disease, autism, epilepsy, Huntington's disease and other CNS disorders. The paper appeared in the online October 5, 2011 edition of PLoS ONE.

David Gerber, PhD, Vice President of CNS Research at Galenea, commented, "Unbiased phenotypic screens of synaptic function using our MANTRA system should lead to breakthrough therapies for a number of debilitating disorders associated with synaptic dysfunctions.  As an illustration of this potential, we have already used MANTRA to discover a new class of pro-cognitive compounds and are using this unique screening technology to progress this novel chemotype through in-house lead optimization."  

Current techniques for studying synaptic physiology are both labor intensive and low throughput, making the dissection of this complex biological process very challenging. For the first time in a peer-reviewed journal, Galenea documents the critical advances necessary for the development of a robust high-throughput synaptic function drug screening assay.  The MANTRA system is capable of operating with exquisite sensitivity, precision, uniformity, and reproducibility. This capacity is exemplified in the manuscript by data from a set of pharmacologically defined compounds.  Screening with MANTRA demonstrated that a number of these compounds mediate their pharmacological effects by specific and previously unknown actions on presynaptic function. The extension of the MANTRA system to genomic screening should uncover new drug targets that will impact not only basic neuroscience research but also drug discovery and development.

"This publication highlights the pioneering work performed by my collaborators at Galenea," stated Timothy Ryan, PhD, Professor of Biochemistry at Weill Cornell Medical College and a co-author of the paper.  "The MANTRA system is a major technological achievement and has significant applications for advancing our understanding of the synaptic dysfunctions associated with many CNS disorders."

About Galenea

Galenea is a leader in the rapidly emerging field of synaptic transmission (ST), the process by which neurons communicate with each other.  Dysfunctions in ST are now widely believed to play a central role in many psychiatric, neurological and neurodegenerative diseases, and modulators of ST therefore have the potential to yield breakthrough treatments. Galenea has developed an innovative ST drug discovery platform that integrates three components: MANTRA™, a high throughput, proprietary screening technology to identify a new generation of small molecule modulators of synaptic transmission; in vivo models using integrated EEG measures of animal behavior to more reliably determine CNS drug efficacy; and human EEG biomarkers, developed in tandem with and informed by our animal EEG data to greatly enhance CNS drug development.   The company is advancing a novel pro-cognitive program derived from the platform and the approach can be extended to address multiple CNS disorders.  Based in Cambridge, MA, Galenea has assembled a compelling scientific team, balancing academic aptitude with industry experience and entrepreneurship.  For more information about Galenea, please visit the company's website at www.galenea.com


'/>"/>
SOURCE Galenea Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Galenea and CHDI Foundation Announce Collaboration to Identify Key Synaptic Dysfunction in Huntingtons Disease
2. Galenea and Otsuka Announce Second Extension to Schizophrenia Research Collaboration
3. Echo Therapeutics Announces Positive Results of Clinical Trial of Its Symphony® Continuous Glucose Monitoring System
4. Express Scripts Announces Revised 2011 Financial Guidance
5. Scios Inc. Announces Agreement with Department of Justice Regarding NATRECOR®
6. Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger
7. Cyberonics Announces Investment in ImThera Medical
8. Kensey Nash Corporation Announces Its First Quarter Fiscal Year 2012 Earnings Release Date and Teleconference
9. Clinical Care Options Announces Addition of ClinicalTrials.gov Database to CCO inPractice™ Point-of-Care Resource
10. ConvaTec Announces Acquisition of Farnhurst Medical
11. Aethlon Medical Announces Hemopurifier® and HER2osome™ Cancer Therapy Presentation at Exosomes and Microvesicles 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... 19, 2017  Hill-Rom Holdings, Inc. (NYSE: HRC), will host ... on Friday, July 28, 2017, beginning at 7:30 a.m. (CDT) ... Dial-in information: To participate in the conference call, dial (877) ... call at least 10 minutes prior to the start to ... Webcast: A simultaneous webcast ...
(Date:6/14/2017)... 14, 2017  ivWatch LLC, a medical device company ... (IV) therapy, is pleased to announce it was the ... Hospital Supplies and Equipment at the 2017 Medical Design ... medtech industry. The award was presented by Medical Device ... Center in New York during ...
(Date:6/12/2017)... June 12, 2017 Kineta, Inc., a biotechnology company ... Kineta Vice President of R&D and Head of Virology ... Pandemic Preparedness for the Northwest and Beyond meeting sponsored ... June 14, 2017 from 8:30-10:30 AM PDT at the Agora ... Dr. Bedard will be joined by other leaders ...
Breaking Medicine Technology:
(Date:6/24/2017)... ... June 24, 2017 , ... Genes Advice, a ... in select Florida and Texas doctors' offices and clinics. This breakthrough testing is ... genetic testing recognizes the role genes play in determining an individual's tolerance of ...
(Date:6/24/2017)... ... , ... Doorknobs are for convenience, deadbolts are for security. , There are ... having an alarm system installed. But unless there is a working deadbolt lock that ... TX Premier Locksmith in Killeen, TX says: “In the majority of home burglaries, intruders ...
(Date:6/23/2017)... MA (PRWEB) , ... June 23, 2017 , ... ... Care Reconciliation Act (BCRA), their proposed healthcare bill to repeal and replace the ... May, the Senate bill would make significant cuts to Medicaid, a public health ...
(Date:6/23/2017)... ... June 23, 2017 , ... Military Connection friend and veteran advocate ... JFK Virgin Atlantic lounge. , Bensko is no stranger to the plight of ... dedicated her life to supporting our wounded veterans. A world-class photographer, her riveting photos ...
(Date:6/23/2017)... ... June 23, 2017 , ... Ensuring meat ... new videos highlight the importance of correctly using a meat thermometer. The videos ... done extensive research on consumer food safety habits. Dr. Bruhn explains the variety ...
Breaking Medicine News(10 mins):